Skip to main content
. Author manuscript; available in PMC: 2021 Nov 16.
Published in final edited form as: Nat Cancer. 2021 Sep 27;2(10):1002–1017.

Extended Data Fig. 8 |. Effects of GSK3685032 and decitabine on complete blood cell counts.

Extended Data Fig. 8 |

a, b, Complete blood cell count (a) at day 28 across all dose groups (n = 5 animals/group; mean ± s.d.). Statistical significance* of treatment versus vehicle was calculated using one-way ANOVA, Dunnett’s multiple comparisons test. Each P value was adjusted to account for multiple comparisons. Table (b) showing output parameters following statistical analysis. Ûsed log10 transformed values due to unequal variance between groups. Ratio represents treatment group normalized to vehicle. c, Complete blood cell count (mean ± s.d.) at day 28 on treatment (n = 5 animals/group) followed by 27 days off treatment (n = 5 animals/group for 15 and 45 mg/kg or n = 8 animals for 30 mg/kg group) with GSK3685032.